New Drug Application Filed for Qutenza 8% Patch To Treat HIV-PN
by Zangani • 10 November 2011 • Pain News
The sNDA seeks approval for a 30-minute application of Qutenza HIV-PN. Qutenza has already been approved by the FDA as a 60-minute application for the management of neuropathic pain associated with postherpetic neuralgia, as well as by the European Commission to treat peripheral neuropathic pain in nondiabetic adults alone or in combination with other medicinal products for pain.